Seratrodast
drug drugOn this page
Also known as A-73001AA-2414ABBOTT 73001ABBOTT-73001ABT-001BronicaNSC-759640SID50125893SID144206327SID170465940
Summary
Seratrodast (CHEMBL70972) is an approved small molecule (ATC R03DX06); indicated across 1 condition including obstructive lung disease.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: R03DX06
- Indications: 1 condition
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL70972 |
| Name | Seratrodast |
| Type | Small molecule |
| Max phase | 4 |
| ATC | R03DX06 |
Also known as: A-73001, AA-2414, ABBOTT 73001, ABBOTT-73001, ABT-001, Bronica, NSC-759640, Seratrodast, SID50125893, SERATRODAST, SID144206327, SID170465940
Patent coverage: 696 distinct patent families (2,990 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Thromboxane A2 receptor, Prostaglandin G/H synthase 2, cGMP-inhibited 3’,5’-cyclic phosphodiesterase 3A, 3’,5’-cyclic-AMP phosphodiesterase 4D, Prostaglandin G/H synthase 1.
Bioactivity
ChEMBL activities: 4 potent at pChembl ≥ 5 of 6 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| TBXA2R | 8.13 | IC50 | 7.4 | nM | CHEMBL_ACT_1304449 |
| Q63921 | 5.94 | AC50 | 1140 | nM | CHEMBL_ACT_25174613 |
| PTGS2 | 5.89 | AC50 | 1300 | nM | CHEMBL_ACT_25166404 |
| TBXA2R | 5.58 | AC50 | 2660 | nM | CHEMBL_ACT_25155398 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).
| Indication | Phase | MONDO | EFO |
|---|---|---|---|
| obstructive lung disease | 4 | MONDO:0002267 | HP:0006536 |
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Indicated for: obstructive lung disease